Teva's EpiPen copy will hit the market even as spot shortages of the ubiquitous auto injector have developed.
Louisiana has proposed a "subscription-based payment model" for hepatitis C drugs it hopes can benefit the state and drugmakers alike.
Mylan unveiled plenty of news in its second-quarter earnings release last week. But there was also some key info it didn’t include.
Bi Jingquan, who headed CFDA for three years, was asked to resign from his current position at the all-powerful State Administration for Market Regulation.
Analysts may have their concerns about Teva’s growth prospects, but Warren Buffett apparently still likes what he sees at the Israeli drugmaker.
Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.
GlaxoSmithKline plans to close its skincare products plants in Sligo, Ireland, and lay off its 165 workers over the next three years.
The FDA this month issued the Apotex Research Private plant in India a warning letter, its third in four years.
Another Chinese product using potentially substandard ingredients has slipped through the regulatory cracks into the U.S.
With biosimilar versions of its top drugs on the horizon, Roche's Genentech unit is parting ways with 223 staffers in California.
 (1).jpg/trump2 (1) (1).jpg?ZYXO5qnC00n3x2BWmWw6pts5r1UYUSjq&itok=Xbv1N-hD "Trump")
